ENXTPA:SANPharmaceuticals
Did Nexviazyme’s Baby-COMET Win and M1Pram Shift Just Reframe Sanofi’s (ENXTPA:SAN) Rare-Disease Focus?
In recent days, Adocia reported that Sanofi’s three-year exclusive negotiation right on the obesity-focused M1Pram combo therapy expired, while separately Sanofi announced positive Phase 3 Baby-COMET results for Nexviazyme in infants with infantile-onset Pompe disease and plans a US label-extension filing in the second half of 2026.
Together with an ongoing EU antitrust probe into alleged disparaging flu-vaccine communications, these developments highlight both Sanofi’s rare-disease R&D...